CD44 and lymphoma: To explore the possibility in more detail, we assessed the consequences of increasing the HA-binding capacity of CD44 in mouse BMDCs using the anti-CD44 mAb IRAWB14, which has been shown to exert such effects in T lymphoma cells by promoting optimal CD44 clustering via an epitope in the N-terminal Link domain (35, 36, 37).